Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982Phase 1Unknown
- Sponsor
- Revolution Medicines
- Start
- Sep 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vociprotafib in solid tumor (advanced stage), sponsored by Revolution Medicines. Primary endpoints: Number of participants with adverse events (AEs) up to 3 years and Number of participants with dose limiting toxicities at 28 days. Status: unknown.
02
Drugs
vociprotafib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03634982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634982.